All In Biotech

Drug Trial Radar · NCT02268253

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)

Last checked: Nov 20, 2026Latest source record: Jan 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

82

Actual

Start

Feb 10, 2016

Primary completion

Mar 27, 2023

Study completion Mar 27, 2023

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, multi-arm trial evaluated the safety and efficacy of tagraxofusp, a cell division cycle protein 123 homolog-targeted therapy, in participants with either CMML or MF. There were 2 CMML cohorts, 1 enrolled participant with CMML (CMML-1 or CMML-2) who were refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy and 1 enrolled treatment-naive participants with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort enrolled participants who were resistant/refractory or intolerant to approved Janus kinase (JAK) therapy (JAK1/JAK2 or JAK2).

Conditions

  • Myelofibrosis
  • Chronic Myelomonocytic Leukemia

Interventions

  • Tagraxofusp InjectionDrug

    Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: 21 days of Cycle 1 (21 days/cycle)
  2. Objective Response Rate (ORR)Time frame: 1145 days

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco

    Clovis, California

  • City of Hope

    Duarte, California

  • University of California, Los Angeles

    Los Angeles, California

  • Stanford Cancer Institute

    Stanford, California

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Indiana Blood and Bone Marrow Transplantation

    Indianapolis, Indiana

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Norton Cancer Institute

    Louisville, Kentucky

  • Dana Farber Cancer Institute (DFCI)

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Weill Cornell Medical Center

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Alberta

    Edmonton, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.